Syndax flags revumenib real-world ROAR study interim data ahead of EHA 2026

Syndax

Syndax

SNDX

0.00
  • Syndax highlighted 12 abstracts on its menin inhibitor Revuforj (revumenib) released ahead of European Hematology Association Congress 2026 in Stockholm, with presentations scheduled for June 12-13.
  • Data across real-world use, frontline combinations, relapsed or refractory settings show consistent anti-leukemia activity across multiple genetic subtypes, with deep responses and tolerability described as favorable.
  • Two post-transplant analyses point to encouraging outcomes versus historical experience, supporting a potential role for revumenib as maintenance to reduce relapse risk.
  • Trial-in-progress abstracts outline late-stage and combination development in newly diagnosed patients, extending revumenib beyond its current relapsed or refractory indications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121031PRIMZONEFULLFEED9718462) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.